Hubei Dinglong Chemical (300054) fair value: what the stock is really worth
As of Oct 28, 2026: fair value (intrinsic value) of Hubei Dinglong Chemical stock ¥25.74, price ¥58.60, upside -56.1%, quality 62 out of 100. Rating: strongly overvalued. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with oneYes, for free
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Oct 27, 2026.
How to read this chart
60‑month range ¥15.29 – ¥105.97 · fair‑value band ¥14.88 – ¥44.78 · the ¥58.60 price screens above the ¥25.74 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Oct 27, 2026.
Follow Hubei Dinglong Chemical in your weekly email
Every Wednesday you see whether Hubei Dinglong Chemical is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Hubei Dinglong CO.,Ltd. engages in research, development, production, and service of circuit design, semiconductor materials, printing and copying general consumables. It offers integrated circuit materials, including polishing pads, polishing fluids, and cleaning fluids.
Show moreShow less
The company provides semiconductor display materials, comprising OLED, LCD, and micro-LED, as well as general consumable and copying products. The company was formerly known as Hubei Dinglong Chemical Co., Ltd and changed its name to Hubei Dinglong CO.,Ltd. in September 2016.
Hubei Dinglong CO.,Ltd. was founded in 2000 and is based in Wuhan, China.
Stock analysis
Hubei Dinglong Chemical (300054) currently trades at ¥58.60, while our model-based Fair Value estimate is ¥25.74, 56.1% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of ¥17.22 per share, and 0 of the 26 models we run sit above the ¥58.60 price.
Bear case: the Asset-Based group reads lowest at ¥3.07, and 26 of the 26 models stay below the price. Data coverage for this calculation is high.
Scenario range: ¥14.88 (bear) to ¥44.78 (bull), the price of ¥58.60 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 62/100 (solid quality), in the Technology sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Hubei Dinglong Chemical reported revenue of 3.6B CNY in FY2025 versus 2.4B CNY in FY2021, a compound +11.5%/yr. Reported net income was 720M CNY in FY2025, compounding +35.5%/yr from FY2021.
Key figures
Market cap 55.3B CNY (≈ $8.3B) Mid · P/E ratio 59.8 · P/S ratio 14.4 · EPS (TTM) ¥0.9800 · Dividend yield 0.2% · Net margin 24.4% · Return on equity 18.0% · Return on assets (EBIT) 7.7%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 77 out of 100 (low confidence).
What moves the price
The share trades about 45% below its 52-week high and 78% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Technology peers we cover trades at −14% fair-value upside, at −56%, 300054 screens richer than that median.
Fair Value models
The price assumes far more growth than our models allow for, so the models scatter widely (¥1.55 to ¥32.09). Read the Fair Value as a cautious anchor, not a price target; the Growth Forecast section shows what the price assumes.
Bear¥14.88Fair Value ¥25.74Bull¥44.78
Price ¥58.60 · Upside -56.1%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then (¥0.7281 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.62/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+8.9%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+10.1%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+14.9%
Start year 2020 (pandemic). Over 10 years: +13.2% a year
Revenue growth 19 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+19.8%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years) (mathematically smoothed) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Smoothed = median of all growth paths between the years of the window (trend line on the logarithm of earnings per share): a single extreme year cannot distort the rate. The reported figure stays in the tooltip.
≈ +35.0%
Earnings growth per share plus dividend.
Earnings per share, growth per year≈ +34.8%
Dividend (yield on the price)0.2%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.base effect: 41.7% / 14.3%
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.−12% → 25%
2025 sits 83% above its own trend. The rate follows the median trend of the last 5 years, not that single year.
⚠ Base effect: the rate starts in the earnings trough around 2020 (starting value 0.13 per share, median 0.30 in 2015 to 2018). It measures the recovery from the trough, not lasting growth.
Growth Forecast
A lot of optimism in the price
The price assumes more growth than the company has delivered so far and more than analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+46.6%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+21.9%
Yearly sales growth analysts expect, extended to five years.
After inflation (China: IMF forecast 1.7% a year to 2030, 1.4% from 2016 to 2025) that is about +44.2% a year for the price and +19.9% for the forecasts.
Compare Hubei Dinglong Chemical with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Semiconductors · 344 stocks
Beats the industry median on 6/15 measures
A mixed picture versus its industry peers.
Valuation
Quality Score62 · Above median
Fair Value upside−56.1% · Below median
Profitability
Return on equity (12 months)18.0% · Top 25%
Return on assets7.9% · Top 25%
Net margin (12 months)24.4% · Top 25%
Operating margin (12 months)33.6% · Top 25%
Growth and dividend
Revenue growth (quarter YoY)−0.3% · Bottom 25%
Dividend yield (12 months)0.2% · Bottom 25%
Balance sheet
Debt / equity0.35× · Highest 25%
Valuation Multiplesvs Semiconductors median · lower = cheaper
P/E (12 months)59.8× · Pricier than median
P/B10.63× · Priciest 25%
P/S (12 months)14.36× · Priciest 25%
Price / free cash flow141.0× · Priciest 25%
EV/EBITDA40.7× · Priciest 25%
PEG0.57× · Cheaper than median
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 0
FUTURE (revenue growth)0· sector 96
PAST (return on equity)72· sector 28
HEALTH (low debt)82· sector 96
DIVIDEND (yield)3· sector 18
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Hubei Dinglong Chemical Fair Value". https://www.fairvalue-calculator.com/stock/300054
Frequently asked questions
Is Hubei Dinglong Chemical (300054) overvalued or undervalued?
As of Oct 27, 2026, our model estimates a fair value of ¥25.74 versus a price of ¥58.60, about −56% upside (overvalued).
What is the fair value of 300054?
Our model-based fair value for Hubei Dinglong Chemical is ¥25.74 (as of Oct 27, 2026), built from audited fundamentals. The current price: ¥58.60.
What is the quality score of 300054?
Hubei Dinglong Chemical has a Quality Score of 62/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Hubei Dinglong Chemical (300054)?
Our model-based price target is the fair value of ¥25.74 (as of Oct 27, 2026) from 26 valuation models. Cautious scenario ¥14.88, optimistic scenario ¥44.78. It is a calculation from audited fundamentals, not an analyst target.
What is the Hubei Dinglong Chemical stock forecast for 2026?
Our models put fair value at ¥25.74, about −56% upside versus a price of ¥58.60 (overvalued). Cautious scenario ¥14.88, optimistic scenario ¥44.78. The calculation is refreshed regularly with new filings.
What is the revenue of Hubei Dinglong Chemical (300054)?
Hubei Dinglong Chemical reported trailing-twelve-month revenue of about 3.9B CNY (latest available figure, as of Oct 27, 2026).
Does Hubei Dinglong Chemical pay a dividend?
Hubei Dinglong Chemical currently shows a dividend yield of 0.17% relative to its recent price (as of Oct 27, 2026).
What growth is priced into Hubei Dinglong Chemical (300054)?
For today's price to be fair in a discounted-cash-flow model, Hubei Dinglong Chemical would have to grow free cash flow by +46.6 % per year for five years (discount rate 9.2 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +14.9 % per year. As of Oct 27, 2026.
What discount rate (WACC) does the fair value of 300054 use?
Our models discount Hubei Dinglong Chemical at 9.2 %: a base by market capitalisation (mid), damped by beta 0.54, country premium for China. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Hubei Dinglong Chemical that is +46.6 % per year a year over ten years, using the same discount rate (9.2 %) and the same formula as our fair value.
How much growth has Hubei Dinglong Chemical (300054) delivered so far?
Over the past 5 years revenue at Hubei Dinglong Chemical grew +14.9 % a year. The price currently implies +46.6 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Hubei Dinglong Chemical (300054) growing?
The median revenue growth in the sector is +9.5 % a year. That is the yardstick for the growth priced into Hubei Dinglong Chemical (+46.6 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Hubei Dinglong Chemical (300054)?
The free-cash-flow yield on the price is 0.71 %: that much free cash flow Hubei Dinglong Chemical produces per unit of market value. When it exceeds the discount rate of our models (9.2 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Hubei Dinglong Chemical (300054)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Hubei Dinglong Chemical it is ¥25.74 per share (as of Oct 27, 2026), against a price of ¥58.60. It is the blended result of 26 valuation models (cash flow, earnings, asset, dividend).
Is Hubei Dinglong Chemical stock overvalued or undervalued in 2026?
As of Oct 27, 2026, 300054 trades above its calculated fair value: price ¥58.60, fair value ¥25.74, a gap of about −56% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 300054?
No. The price is what the market pays today (¥58.60); the fair value is what the company's own numbers justify (¥25.74). For Hubei Dinglong Chemical the two are ¥32.86 per share apart. That gap is exactly why we show both numbers side by side.
How much is Hubei Dinglong Chemical worth?
The market values Hubei Dinglong Chemical at about 55.3B CNY (market capitalisation, as of Oct 27, 2026). Per share that is ¥58.60; our models calculate a fair value of ¥25.74 per share.
What do the bullish and bearish scenarios say about 300054?
Our models span a range for Hubei Dinglong Chemical: cautious scenario ¥14.88, base ¥25.74, optimistic ¥44.78 per share (as of Oct 27, 2026, price ¥58.60). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 300054?
Hubei Dinglong Chemical trades at a price-to-earnings ratio of 59.8 (as of Oct 27, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of ¥25.74 is built from several models across several years. Other multiples: PEG 0.6, P/B 10.6, P/S 14.4, EV/EBITDA 40.7.
What is the PEG ratio of 300054?
The PEG ratio of Hubei Dinglong Chemical is 0.57 (P/E divided by earnings growth, as of Oct 27, 2026). That is below 1, so growth is priced more cheaply than the earnings multiple alone suggests.
How solid is the balance sheet of Hubei Dinglong Chemical (300054)?
Balance-sheet figures for Hubei Dinglong Chemical (as of Oct 27, 2026): return on equity 18.0%, debt of 0.35 per unit of equity. They feed the Quality Score of 62/100, which measures business quality independently of the share price.
How far is 300054 from its 52-week high?
Hubei Dinglong Chemical trades at ¥58.60, about 45% below its 52-week high of ¥105.97 and 78% above the low of ¥33.01 (as of Oct 28, 2026). Distance from the high says nothing about value: that is what the fair value of ¥25.74 is for.
Which stocks are comparable to Hubei Dinglong Chemical?
From the same area (Technology) we also value NVIDIA Corporation, Taiwan Semiconductor Manufacturing Company, Broadcom Inc, Micron Technology, Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Hubei Dinglong Chemical stock attractive at the current price?
The data as of Oct 27, 2026: price ¥58.60, calculated fair value ¥25.74 (−56%), Quality Score 62/100, from 26 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 300054 calculated?
We run Hubei Dinglong Chemical through 26 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of ¥25.74, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.4 % above its aggregate fair value. Hubei Dinglong Chemical itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Hubei Dinglong Chemical (300054)?
The closing price on Oct 28, 2026 was ¥58.60. Our model-based fair value is ¥25.74, about −56% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Hubei Dinglong Chemical right now?
The price sits above even our optimistic bull case (¥44.78). The favourable scenario is already priced in. The model range is unusually wide (¥14.88 to ¥44.78). The outcome hinges heavily on assumptions, so read the point estimate with caution. Solid but not exceptional quality (62/100) and above fair value, neither a clear bargain nor a standout compounder.
Where does the earnings growth of Hubei Dinglong Chemical (300054) come from?
Earnings per share at Hubei Dinglong Chemical grew +10.2 % a year from 2014 to 2025. Broken into its drivers: revenue per share +11.1 %, EBIT margin −0.2 %, tax rate +0.5 %, residual (interest, one-offs) −1.1 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.
Key figures of Hubei Dinglong Chemical
How large is the market capitalisation of Hubei Dinglong Chemical (300054)?
The market capitalisation of Hubei Dinglong Chemical is 55.3B CNY (≈ $8.3B). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Hubei Dinglong Chemical (300054)?
The price-to-sales ratio of Hubei Dinglong Chemical is 14.4 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Hubei Dinglong Chemical (300054)?
Earnings per share at Hubei Dinglong Chemical are ¥0.9800 (price ÷ EPS = P/E 59.8). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Hubei Dinglong Chemical (300054)?
The dividend yield of Hubei Dinglong Chemical is 0.2% (payout 10.2%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Hubei Dinglong Chemical (300054)?
The net margin of Hubei Dinglong Chemical is 24.4% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Hubei Dinglong Chemical (300054)?
The return on equity (ROE) of Hubei Dinglong Chemical is 18.0% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Hubei Dinglong Chemical (300054)?
On an EBIT basis the return on assets of Hubei Dinglong Chemical is 7.7% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Hubei Dinglong Chemical (300054)?
The operating margin of Hubei Dinglong Chemical is 33.6% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Hubei Dinglong Chemical (300054)?
Revenue at Hubei Dinglong Chemical is growing −0.3% versus a year earlier (3y avg +10.1%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Hubei Dinglong Chemical (300054)?
Earnings per share at Hubei Dinglong Chemical are growing +61.5% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Hubei Dinglong Chemical (300054) carry?
The net debt of Hubei Dinglong Chemical is 818M CNY (fiscal year 2025, ≈ 2.1 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Hubei Dinglong Chemical in the live analysis
One click puts Hubei Dinglong Chemical on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 28,000+ stock screener.
Broad data
Oct 27, 2026